

GLP-1 Pipeline Update: August 2026

As the GLP-1 pipeline continues to grow, Prime Therapeutics actively monitors this emerging landscape and provides a credible clinical snapshot of what is on the horizon. The below table displays the earliest potential approval dates of the agents listed. Dates are based on manufacturer-published announcements or communications, or are estimated based on study completion dates, and may change as more information becomes available.

	Diabetes + diabetes-related conditions			Obesity or overweight + related conditions							Other
Drug/Dosage form	T2DM	T2DM + CVD	Diabetic nephropathy	Obesity or overweight	Obesity or overweight + CVD	Obesity or overweight + CLBP	Obesity or overweight + HTN	Obesity or overweight + OA of knee	Obesity or overweight + OSA	T1DM ± obesity or overweight	MASH
Amgen											
maridebart cafraglutide/SC				2028							
AstraZeneca											
exenatide (Bydureon BCise)/SC	FDA approved (≥10 years of age)										
exenatide (generic for Byetta)*/SC	FDA approved (≥10 years of age)										
Eli Lilly											
dulaglutide (Trulicity)/SC	FDA approved (≥10 years of age)	FDA approved									
tirzepatide (Mounjaro)/SC	FDA approved (≥10 years of age)	FDA decision Q3 2026								2028	
tirzepatide (Zepbound)/SC				FDA approved					FDA approved		
orforglipron (Foundayo)/oral	FDA decision Q4 2026			FDA approved			2028		2027		

	Diabetes + diabetes-related conditions			Obesity or overweight + related conditions							Other
Drug/Dosage form	T2DM	T2DM + CVD	Diabetic nephropathy	Obesity or overweight	Obesity or overweight + CVD	Obesity or overweight + CLBP	Obesity or overweight + HTN	Obesity or overweight + OA of knee	Obesity or overweight + OSA	T1DM ± obesity or overweight	MASH
retatrutide/SC	2027			2027	2027	2028		2027	2027		
Novo Nordisk											
liraglutide (Victoza)*/SC	FDA approved (≥10 years of age)	FDA approved									
liraglutide (Saxenda)/SC				FDA approved (≥12 years of age)							
liraglutide + insulin degludec (Xultophy)/SC	FDA approved										
semaglutide (Ozempic) 1.5 mg, 4 mg & 9 mg/oral	FDA approved	FDA approved									
semaglutide (Rybelsus) 3 mg, 7 mg & 14 mg/oral	FDA approved	FDA approved									
semaglutide (Ozempic) 25 mg/oral	FDA decision Q4 2026										
semaglutide (Ozempic) 1 mg & 2 mg/SC	FDA approved	FDA approved	FDA approved								
semaglutide (Wegovy) 1.5 mg, 4 mg & 9 mg/oral				FDA approved	FDA approved						
semaglutide (Wegovy) 25 mg/oral				FDA approved	FDA approved						FDA decision 2026–2027

	Diabetes + diabetes-related conditions			Obesity or overweight + related conditions							Other
Drug/Dosage form	T2DM	T2DM + CVD	Diabetic nephropathy	Obesity or overweight	Obesity or overweight + CVD	Obesity or overweight + CLBP	Obesity or overweight + HTN	Obesity or overweight + OA of knee	Obesity or overweight + OSA	T1DM ± obesity or overweight	MASH
semaglutide (Wegovy) 1.7 mg & 2.4 mg/SC				FDA approved (≥12 years of age)	FDA approved						FDA approved
semaglutide (Wegovy HD) 7.2 mg/SC				FDA approved							
cagrilintide + semaglutide/SC	2028			<i>FDA decision December 2026</i>							
Sanofi											
lixisenatide + insulin glargine (Soliqua)/SC	FDA approved										
Viking											
VK2735/SC				2028							
Zealand, Boehringer Ingelheim											
survodutide/SC				2027	2027						2028 (+obesity)

*Generics available

Glossary

CLBP chronic low back pain

CVD cardiovascular disease

FDA Food and Drug Administration

GLP-1 glucagon-like peptide-1 receptor agonist

HTN hypertension

MASH metabolic dysfunction-associated steatohepatitis

OA osteoarthritis

OSA obstructive sleep apnea

SC subcutaneous

T1DM type 1 diabetes mellitus

Disclaimer

The drug pipeline is fluid; the dates and information within this publication are subject to change. Nothing herein is or shall be construed as a promise or representation regarding past or future events and Prime Therapeutics expressly disclaims any and all liability relating to the use of or reliance on the information contained in this presentation. The information contained in this publication is intended for educational purposes only and should not be considered clinical, financial or legal advice. By receipt of this publication, each recipient agrees that the information contained herein will be kept confidential and that the information will not be photocopied, reproduced, distributed to or disclosed to others at any time without the prior written consent of Prime Therapeutics.

All brand names are property of their respective owners.